Neximmune, Inc. Stock Price, News & Analysis

NexImmune, a clinical-stage biotechnology company, announced CEO Scott Carmer's participation in the LLS TAP panel discussion on January 21, 2022, at 12:00 p.m. ET. The discussion focuses on advancements in next-generation cell therapies. NexImmune has received ongoing support from the Leukemia & Lymphoma Society, benefiting from investments since 2017 to enhance its Phase 1/2 studies in treating blood cancers. Their proprietary AIM™ nanoparticle technology aims to generate specific and durable immune responses, with lead programs, NEXI-001 and NEXI-002, currently in clinical trials.

NexImmune, Inc. (Nasdaq: NEXI) announces the establishment of its Autoimmune and Infectious Disease Scientific Advisory Board (AI & ID SAB), featuring notable experts in immunology and T cell biology. This strategic move aims to enhance the company's AIM nanotechnology platform, which directs antigen-specific T cells for targeted immune responses. Jerry Zeldis, EVP of R&D, emphasized the board's role in refining decisions as NexImmune expands its therapeutic pipeline, especially for its lead programs NEXI-001 and NEXI-002, both in Phase 1/2 clinical trials.

NexImmune, Inc. (Nasdaq: NEXI) announced preliminary Phase 1/2 results for NEXI-002, a novel immunotherapy for relapsed/refractory multiple myeloma presented at the 63rd ASH Annual Meeting. The study involved patients with an average of 7.6 prior therapy lines, displaying a favorable safety profile with no severe toxicities. Early data suggests NEXI-002 shows immunologic activity, with a stable disease duration of 2 to 3.5 months in patients. These results encourage ongoing evaluations and potential applications in lower-burden plasma cell dyscrasias.

NexImmune (Nasdaq: NEXI) reported a net loss of $14.6M for Q3 2021, translating to a GAAP loss per share of $0.65. Cash reserves declined to $93.2M from $102.8M in Q2 2021, expected to last through Q4 2022. The company continues to advance its Phase 1/2 trials for NEXI-001 and NEXI-002, with updates forthcoming in 2022. Collaborations with Yale University on Type 1 Diabetes using AIM INJ nanoparticles signify strategic expansion. R&D expenses surged to $11.3M, reflecting higher trial costs and personnel expenses.

NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology firm, announced plans to report its third quarter financial results and provide a corporate update on November 12, 2021, before market open. The press release will be accessible on the company's investor website. NexImmune is focused on innovative immunotherapy development utilizing its AIM™ nanoparticle technology, with lead programs NEXI-001 and NEXI-002 currently in Phase 1/2 trials targeting relapsed AML and multiple myeloma, respectively.

NexImmune, a clinical-stage biotechnology company (Nasdaq: NEXI), announced that CEO Scott Carmer will present at the 2021 Cantor Virtual Global Healthcare Conference on September 29, 2021, at 2:00 PM ET. The event will be accessible through NexImmune's Investor Relations page, with a replay available for 90 days. NexImmune focuses on immunotherapy leveraging T cells for targeted immune responses, utilizing a proprietary AIM™ nanoparticle technology. The company’s lead programs, NEXI-001 and NEXI-002, are in Phase 1/2 trials for relapsed AML and multiple myeloma, respectively.

NexImmune, a clinical-stage biotechnology company, announced that CEO Scott Carmer will participate in a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 10, 2021, at 1:15 p.m. ET. The chat will be available via webcast on the company's Investor Relations page, with a replay lasting 30 days. NexImmune focuses on immunotherapy using its AIM nanoparticle technology to generate targeted immune responses through T cells. Its lead programs, NEXI-001 and NEXI-002, are in Phase 1/2 trials for treating relapsed AML and refractory multiple myeloma.

NexImmune, Inc. (NEXI) announced significant clinical developments, including its first solid tumor indication targeting HPV-associated malignancies. During Q2 2021, NexImmune reported a cash position of $102.8M, down from $118.1M in Q1. The company recorded a net loss of $12.2M, equating to a GAAP loss per share of $0.54. R&D expenses rose to $8.1M, reflecting ongoing clinical trials. The company anticipates completing enrollment in its Phase I/II trials for NEXI-001 and NEXI-002 and revealing additional data at upcoming scientific conferences.